Home/Pipeline/Endometriosis Program

Endometriosis Program

Endometriosis

DiscoveryActive

Key Facts

Indication

Endometriosis

Phase

Discovery

Status

Active

Company

Cyclana Bio

About Cyclana Bio

Cyclana Bio is an early-stage biotech targeting significant unmet needs in women's health, with an initial focus on endometriosis. The company's core innovation is a proprietary platform that analyzes menstrual fluid and the tissue extracellular matrix (ECM) to stratify disease, build human-relevant assays, and discover novel drug targets. Founded by alumni of Cambridge University and Altos Labs, the team combines expertise in biophysics, computational biology, and translational science to de-risk therapeutic discovery from the tissue level up. While currently in pre-clinical platform and target discovery, Cyclana aims to build a pipeline of first-in-class therapies for complex gynecological conditions.

View full company profile

Therapeutic Areas

Endometriosis Women's Health

Other Endometriosis Drugs

Drug	Company	Phase	Status
Promarker™Endo	Proteomics International	Late‑stage validation	Active
EV‑Endo	Cartherics	Preclinical	Active
Endometriosis Genetic Study	Juneau Biosciences	Discovery	Active
Potential Diagnostic Development	Juneau Biosciences	Research	Active
Endometriosis Discovery Program	Metri Bio	Discovery	Active
Endometriosis Test Suite	Heranova Lifesciences	Pre-clinical	Active
EndomTest	Kephera Diagnostics	Commercial (LDT)	Active
ENDO-205	EndoCyclic Therapeutics	Phase 1	Active
Undisclosed Immunotherapy	Apheon Bioscience	Preclinical	Active
FMC	FimmCyte	Pre-clinical	Active
ABC-201	Abcely	Preclinical	Active
ERβ Modulator Program	Cadenza Bio	Preclinical	Active